Rhumbline Advisers Akebia Therapeutics, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 365,035 shares of AKBA stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
365,035
Previous 282,066
29.41%
Holding current value
$1.07 Million
Previous $541,000
145.47%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding AKBA
# of Institutions
170Shares Held
106MCall Options Held
134KPut Options Held
262K-
Vanguard Group Inc Valley Forge, PA14.6MShares$42.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$34 Million0.0% of portfolio
-
State Street Corp Boston, MA8MShares$23.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.07MShares$17.7 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$16.8 Million20.26% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $537M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...